Dermata Therapeutics Inc (DRMA) — Cash Flow-to-Debt Ratio
Dermata Therapeutics Inc (DRMA) has a Cash Flow-to-Debt Ratio of -0.81x as of December 2025, meaning its operating cash flow of $-1.33 Million could theoretically repay -1% of its total liabilities ($1.64 Million) in one year. See working capital position of Dermata Therapeutics Inc to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Dermata Therapeutics Inc Cash Flow-to-Debt Ratio (2019–2025)
Historical debt coverage capacity for Dermata Therapeutics Inc across 7 annual periods. Also explore DRMA shareholders equity momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Dermata Therapeutics Inc (2019–2025)
Year-by-year debt coverage analysis for Dermata Therapeutics Inc. For market capitalisation and broader financial context, see Dermata Therapeutics Inc (DRMA) total market value.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -4.73x | $-7.76 Billion | $1.64 Billion | ▲ +16.4% |
| 2024 | -5.66x | $-11.16 Million | $1.97 Million | ▼ -43.3% |
| 2023 | -3.95x | $-6.41 Million | $1.62 Million | ▲ +58.8% |
| 2022 | -9.57x | $-8.83 Million | $922.63K | ▼ -155.1% |
| 2021 | -3.75x | $-5.69 Million | $1.52 Million | ▼ -252.5% |
| 2020 | -1.06x | $-4.03 Million | $3.78 Million | ▲ +38.2% |
| 2019 | -1.72x | $-3.92 Million | $2.28 Million | — |